SI2900230T1 - Sestavki za zdravljenje debelosti in postopki njihove uporabe - Google Patents
Sestavki za zdravljenje debelosti in postopki njihove uporabeInfo
- Publication number
- SI2900230T1 SI2900230T1 SI201331170T SI201331170T SI2900230T1 SI 2900230 T1 SI2900230 T1 SI 2900230T1 SI 201331170 T SI201331170 T SI 201331170T SI 201331170 T SI201331170 T SI 201331170T SI 2900230 T1 SI2900230 T1 SI 2900230T1
- Authority
- SI
- Slovenia
- Prior art keywords
- obesity
- compounds
- treatment
- methods
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261706153P | 2012-09-27 | 2012-09-27 | |
PCT/US2013/061911 WO2014052583A1 (en) | 2012-09-27 | 2013-09-26 | Compounds for the treatment of obesity and methods of use thereof |
EP13773562.7A EP2900230B1 (en) | 2012-09-27 | 2013-09-26 | Compounds for the treatment of obesity and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2900230T1 true SI2900230T1 (sl) | 2019-01-31 |
Family
ID=49304418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201331170T SI2900230T1 (sl) | 2012-09-27 | 2013-09-26 | Sestavki za zdravljenje debelosti in postopki njihove uporabe |
Country Status (21)
Country | Link |
---|---|
US (5) | US9968575B2 (sl) |
EP (3) | EP3434268B1 (sl) |
JP (2) | JP6480864B2 (sl) |
CN (3) | CN104822374A (sl) |
AU (3) | AU2013323528B2 (sl) |
BR (1) | BR112015006848A2 (sl) |
CA (2) | CA2886393C (sl) |
CY (1) | CY1121166T1 (sl) |
DK (1) | DK2900230T3 (sl) |
ES (1) | ES2696626T3 (sl) |
HK (1) | HK1213190A1 (sl) |
HR (1) | HRP20181879T1 (sl) |
HU (1) | HUE040496T2 (sl) |
LT (1) | LT2900230T (sl) |
PL (1) | PL2900230T3 (sl) |
PT (1) | PT2900230T (sl) |
RS (1) | RS58010B1 (sl) |
RU (2) | RU2768868C2 (sl) |
SI (1) | SI2900230T1 (sl) |
TR (1) | TR201815668T4 (sl) |
WO (1) | WO2014052583A1 (sl) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2900230T3 (en) | 2012-09-27 | 2018-11-12 | Childrens Medical Ct Corp | RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF |
EP3122347B1 (en) * | 2014-03-26 | 2020-06-03 | The Children's Medical Center Corporation | Celastrol derivatives for the treatment of obesity |
WO2015153933A1 (en) * | 2014-04-03 | 2015-10-08 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
CN105985401B (zh) * | 2015-02-16 | 2020-10-09 | 上海华拓医药科技发展有限公司 | 一种雷公藤红素衍生物、其制备方法及用途 |
EP3364956A4 (en) | 2015-10-23 | 2019-05-01 | ERX Pharmaceuticals, Inc. | CELASTROL ANALOGUES |
CN106905404B (zh) * | 2017-01-13 | 2019-08-27 | 广东工业大学 | 熊果酸衍生物及其制备方法和应用 |
KR102470686B1 (ko) * | 2022-06-07 | 2022-11-23 | 서울대학교산학협력단 | 디메틸제일아스테럴을 포함하는 대사성 질환 예방 또는 치료용 약학 조성물 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU531759B2 (en) | 1978-04-17 | 1983-09-08 | Ici Ltd. | Electrostatic spraying |
GB8504253D0 (en) | 1985-02-19 | 1985-03-20 | Ici Plc | Electrostatic spraying apparatus |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
US6350730B1 (en) | 1994-08-17 | 2002-02-26 | The Rockefeller University | OB polypeptides and modified forms as modulators of body weight |
US6429290B1 (en) | 1994-08-17 | 2002-08-06 | The Rockefeller University | OB polypeptides, modified forms and derivatives |
US5827734A (en) | 1995-01-20 | 1998-10-27 | University Of Washington | Materials and methods for determining ob protein in a biological sample |
US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
US5552523A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
US5552522A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
US5532336A (en) | 1995-01-31 | 1996-07-02 | Eli Lilly And Company | Anti-obesity proteins |
AU6028396A (en) | 1995-06-07 | 1996-12-30 | Amgen, Inc. | Ob protein compositions and method |
EP0836479A2 (en) | 1995-06-30 | 1998-04-22 | Eli Lilly And Company | Methods for treating diabetes |
AU6688896A (en) | 1995-08-17 | 1997-03-12 | Amgen, Inc. | Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions |
US5650167A (en) * | 1995-11-16 | 1997-07-22 | Dawa Incorporated | Method and composition for treating hepatitis B |
AU7607496A (en) | 1995-11-22 | 1997-06-11 | Amgen, Inc. | Methods of increasing lean tissue mass using ob protein compositions |
US20030040467A1 (en) | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
WO1997038014A1 (en) | 1996-04-04 | 1997-10-16 | Amgen Inc. | Fibulin pharmaceutical compositions and related methods |
WO1998008512A1 (en) | 1996-08-30 | 1998-03-05 | Amgen Inc. | Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor |
PL332458A1 (en) | 1996-09-20 | 1999-09-13 | Hoechst Ag | Application of leptin antagonists in treating insulin resistance in cases of diabeted of type ii |
DE69730093T2 (de) | 1996-10-31 | 2006-07-20 | Takeda Pharmaceutical Co. Ltd. | Zubereitung mit verzögerter Freisetzung |
US5880116A (en) * | 1996-12-13 | 1999-03-09 | Neurocal International | Use of celastrol to treat alzheimer's disease |
ATE351910T1 (de) | 1996-12-20 | 2007-02-15 | Amgen Inc | Ob-fusionsprotein enthaltende zusammensetzungen und verfahren |
CA2286098C (en) | 1997-04-17 | 2009-07-07 | Amgen Inc. | Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods |
JP2002504102A (ja) | 1997-06-06 | 2002-02-05 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 糖尿病治療のためのレプチン拮抗物質の使用 |
US7052678B2 (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties |
US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
ATE280588T1 (de) | 1998-08-10 | 2004-11-15 | Amgen Inc | Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren |
EP1118001A1 (en) | 1998-10-02 | 2001-07-25 | Amgen Inc. | Method to determine a predisposition to leptin treatment |
US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
WO2000047741A1 (en) | 1999-02-12 | 2000-08-17 | Amgen Inc. | Glycosylated leptin compositions and related methods |
ATE475094T1 (de) | 2001-10-22 | 2010-08-15 | Amgen Inc | Verwendung von leptin zur behandlung von lipoatrophie im menschen und verfahren zur bestimmmung einer prädisposition gegenüber der behandlung |
NZ539642A (en) * | 2002-10-21 | 2007-01-26 | Metaproteomics Llc | Compositions containing extracts from hops in combination with a second component for treating inflammatory response |
AU2003290563A1 (en) | 2002-10-31 | 2004-05-25 | Clf Medical Technology Acceleration Program, Inc. | Leptin-related peptides |
RU2346688C2 (ru) * | 2002-12-06 | 2009-02-20 | Фиброген, Инк. | Регулирование содержания жира |
EP1715539B1 (en) | 2004-01-16 | 2012-11-07 | Mitsubishi Materials Corporation | Separator for fuel cell, method of producing separator, and solid oxide fuel cell |
US20060253100A1 (en) * | 2004-10-22 | 2006-11-09 | Medtronic, Inc. | Systems and Methods to Treat Pain Locally |
JP4169777B2 (ja) | 2005-09-30 | 2008-10-22 | 森永乳業株式会社 | インスリン抵抗性改善剤 |
EP2604269B1 (en) | 2005-11-01 | 2014-09-24 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones with therapeutic properties |
JP2009530399A (ja) | 2006-03-22 | 2009-08-27 | シンデクサ ファーマシューティカルズ コーポレーション | Erストレスに関連する疾病の治療のための化合物及び方法 |
WO2007117466A2 (en) * | 2006-03-31 | 2007-10-18 | Massachusetts Institute Of Technology | Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors |
TW200824678A (en) | 2006-08-11 | 2008-06-16 | Combinatorx Inc | Methods and compositions for the treatment of neurodegenerative disorders |
JPWO2008020622A1 (ja) * | 2006-08-17 | 2010-01-07 | 杏林製薬株式会社 | 新規なチエノ[2,3−d]ピリミジン化合物 |
US20100240581A1 (en) * | 2006-11-13 | 2010-09-23 | The Trustees Of Columbia University In The City Of New York | Selective proteasome inhibitors for treating diabetes |
CN101279995A (zh) * | 2007-04-03 | 2008-10-08 | 烟台靶点药物研究有限公司 | 一种雷公藤红素盐及其制备方法与用途 |
WO2009026163A1 (en) | 2007-08-17 | 2009-02-26 | Burnham Institute For Medical Research | Compositions and methods for inhibiting growth and metastasis of melanoma |
EP2219664A1 (en) * | 2007-11-14 | 2010-08-25 | Amylin Pharmaceuticals, Inc. | Methods for treating obesity and obesity related diseases and disorders |
CN101434635B (zh) | 2007-11-16 | 2012-05-16 | 上海华拓医药科技发展股份有限公司 | 一类具抗肿瘤活性的水溶性酚性三萜化合物及其制备方法 |
WO2009067245A2 (en) * | 2007-11-20 | 2009-05-28 | University Of Florida Research Foundation, Inc. | Compositions and methods for tissue repair |
JP2011511007A (ja) * | 2008-02-01 | 2011-04-07 | ザ スクリプス リサーチ インスティチュート | タンパク質ホメオスタシスの機能不全を特徴とする状態を治療するための方法 |
CN101352444A (zh) * | 2008-09-11 | 2009-01-28 | 中国科学院广州生物医药与健康研究院 | 雷公藤红素在制药中的新应用 |
US9132108B2 (en) | 2009-04-17 | 2015-09-15 | Hiroshima University | Pharmaceutical composition for ameliorating and/or preventing leptin resistance, and use thereof |
CN101704874A (zh) * | 2009-11-26 | 2010-05-12 | 中国药科大学 | 五环三萜及其衍生物的二甲双胍盐、其制备方法及医药用途 |
JP5990160B2 (ja) | 2010-04-12 | 2016-09-07 | リアタ ファーマシューティカルズ インコーポレイテッド | 抗酸化炎症モジュレーターを使用して肥満を処置する方法 |
CN101805390B (zh) | 2010-04-13 | 2012-07-18 | 暨南大学 | 一种雷公藤红素衍生物及其用途 |
CN102309494A (zh) * | 2010-07-01 | 2012-01-11 | 嘉兴学院 | 扁蒴藤素作为炎性细胞因子抑制剂的医药用途 |
AU2011292959B2 (en) | 2010-08-23 | 2016-06-09 | Suzhou Neupharma Co., Ltd. | Certain chemical entities, compositions, and methods |
WO2012036293A1 (ja) * | 2010-09-17 | 2012-03-22 | 武田薬品工業株式会社 | 糖尿病治療剤 |
KR101180387B1 (ko) | 2011-11-21 | 2012-09-10 | 동국대학교 산학협력단 | 엣지 추출을 위한 이미지 센서 및 이를 이용한 엣지 이미지 생성 방법. |
WO2013177535A2 (en) | 2012-05-25 | 2013-11-28 | Berg Pharma Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta |
DK2900230T3 (en) | 2012-09-27 | 2018-11-12 | Childrens Medical Ct Corp | RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF |
CN103524592B (zh) | 2013-09-27 | 2015-08-05 | 安徽医科大学 | 一种雷公藤红素衍生物、该衍生物的生物盐及其制备方法与用途 |
US9601471B2 (en) | 2015-04-23 | 2017-03-21 | Apple Inc. | Three layer stack structure |
-
2013
- 2013-09-26 DK DK13773562.7T patent/DK2900230T3/en active
- 2013-09-26 LT LTEP13773562.7T patent/LT2900230T/lt unknown
- 2013-09-26 US US14/431,412 patent/US9968575B2/en active Active
- 2013-09-26 BR BR112015006848A patent/BR112015006848A2/pt not_active Application Discontinuation
- 2013-09-26 AU AU2013323528A patent/AU2013323528B2/en active Active
- 2013-09-26 CA CA2886393A patent/CA2886393C/en active Active
- 2013-09-26 EP EP18181547.3A patent/EP3434268B1/en active Active
- 2013-09-26 ES ES13773562T patent/ES2696626T3/es active Active
- 2013-09-26 EP EP13773562.7A patent/EP2900230B1/en active Active
- 2013-09-26 CN CN201380061929.9A patent/CN104822374A/zh active Pending
- 2013-09-26 JP JP2015534652A patent/JP6480864B2/ja active Active
- 2013-09-26 SI SI201331170T patent/SI2900230T1/sl unknown
- 2013-09-26 EP EP22168909.4A patent/EP4082541A1/en active Pending
- 2013-09-26 RU RU2018112067A patent/RU2768868C2/ru active
- 2013-09-26 TR TR2018/15668T patent/TR201815668T4/tr unknown
- 2013-09-26 CA CA3030272A patent/CA3030272C/en active Active
- 2013-09-26 CN CN202010540739.7A patent/CN111529535A/zh active Pending
- 2013-09-26 PL PL13773562T patent/PL2900230T3/pl unknown
- 2013-09-26 PT PT13773562T patent/PT2900230T/pt unknown
- 2013-09-26 RS RS20181365A patent/RS58010B1/sr unknown
- 2013-09-26 WO PCT/US2013/061911 patent/WO2014052583A1/en active Application Filing
- 2013-09-26 HU HUE13773562A patent/HUE040496T2/hu unknown
- 2013-09-26 CN CN202010540726.XA patent/CN111529534A/zh active Pending
- 2013-09-26 RU RU2015115696A patent/RU2650646C2/ru active
-
2016
- 2016-02-02 HK HK16101217.7A patent/HK1213190A1/zh unknown
- 2016-10-21 AU AU2016247206A patent/AU2016247206B2/en active Active
-
2017
- 2017-07-07 US US15/644,247 patent/US9925161B2/en active Active
-
2018
- 2018-02-28 US US15/908,571 patent/US10653654B2/en active Active
- 2018-11-01 AU AU2018256619A patent/AU2018256619B2/en active Active
- 2018-11-08 CY CY20181101181T patent/CY1121166T1/el unknown
- 2018-11-08 HR HRP20181879TT patent/HRP20181879T1/hr unknown
-
2019
- 2019-02-08 JP JP2019021437A patent/JP6743211B2/ja active Active
-
2020
- 2020-04-28 US US16/860,232 patent/US11045439B2/en active Active
-
2021
- 2021-05-21 US US17/326,944 patent/US12064408B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL261768B (en) | Devices and methods for tissue treatment | |
HK1208439A1 (en) | 5-azaindazole compounds and methods of use 5- | |
HRP20181879T1 (hr) | Spojevi za liječenje pretilosti i postupci za njihovu upotrebu | |
EP2867209A4 (en) | COMPOUNDS AND THEIR THERAPEUTIC USES | |
HK1200348A1 (en) | Methods and materials for treatment of pompes disease | |
HK1207860A1 (en) | 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders 2--5---2h--3- | |
EP2867239A4 (en) | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | |
SG2014014724A (en) | METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS | |
HRP20190219T1 (hr) | Spojevi za tretman pretilosti i postupci za njihovu uporabu | |
ZA201408055B (en) | Compositions and methods for the treatment of local pain | |
HK1211221A1 (en) | Formulations for the treatment and prevention of obesity | |
HRP20181761T1 (hr) | Novi pripravak alfentanila za liječenje akutne boli | |
HK1209639A1 (en) | Gpbp-1 inhibition and its therapeutic use gpbp-1 | |
ZA201501503B (en) | Bio-inoculant and use thereof for treatment of effluents | |
ZA201408065B (en) | Compositions and methods for the treatment of diabetes | |
EP2793875A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF A DIVERTICULOSE | |
PT2819655T (pt) | Utilização de modafinil no tratamento de cocainómanos | |
HK1210421A1 (en) | Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders -4--20--3- |